Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 89

1.

Investigation of the influence of xenoreactive antibodies on activation of complement and coagulation in an ex vivo perfusion animal study using porcine kidneys.

Ramackers W, Werwitzke S, Klose J, Friedrich L, Johanning K, Bergmann S, Klempnauer J, Winkler M, Tiede A.

Transpl Int. 2018 Dec 30. doi: 10.1111/tri.13396. [Epub ahead of print]

PMID:
30597634
2.

Long-term safety and efficacy of turoctocog alfa in prophylaxis and treatment of bleeding episodes in severe haemophilia A: Final results from the guardian 2 extension trial.

Lentz SR, Janic D, Kavakli K, Miljic P, Oldenburg J, C Ozelo M, Santagostino E, Suzuki T, Zupancic Šalek S, Korsholm L, Matytsina I, Tiede A.

Haemophilia. 2018 Nov;24(6):e391-e394. doi: 10.1111/hae.13617. Epub 2018 Nov 6.

PMID:
30402994
3.
4.

Lessons from a systematic literature review of the effectiveness of recombinant factor VIIa in acquired haemophilia.

Tiede A, Worster A.

Ann Hematol. 2018 Oct;97(10):1889-1901. doi: 10.1007/s00277-018-3372-z. Epub 2018 May 26. Review. Erratum in: Ann Hematol. 2018 Dec;97(12):2531.

5.

Einladung zur Mitgliederversammlung.

Tiede A.

Hamostaseologie. 2018 Feb;38(1):52. doi: 10.1055/s-0038-1637801. Epub 2018 Mar 1. German. No abstract available.

PMID:
29536481
6.

Pathology in Practice.

Ulrich R, Rosa S, Tiede A, Baumgärtner W.

J Am Vet Med Assoc. 2017 Nov 15;251(10):1157-1159. doi: 10.2460/javma.251.10.1157. No abstract available.

PMID:
29099258
7.

Co-morbidities and bleeding in elderly patients with haemophilia-A survey of the German, Austrian and Swiss Society of Thrombosis and Haemostasis Research (GTH).

Miesbach W, Reitter-Pfoertner SE, Klamroth R, Langer F, Wolf HH, Tiede A, Siegmund B, Scholz U, Müller PR, Eichler H, Pabinger I.

Haemophilia. 2017 Sep;23(5):721-727. doi: 10.1111/hae.13296. Epub 2017 Jun 21.

PMID:
28636084
8.

Pathogen reduction/inactivation of products for the treatment of bleeding disorders: what are the processes and what should we say to patients?

Di Minno G, Navarro D, Perno CF, Canaro M, Gürtler L, Ironside JW, Eichler H, Tiede A.

Ann Hematol. 2017 Aug;96(8):1253-1270. doi: 10.1007/s00277-017-3028-4. Epub 2017 Jun 18. Review.

9.

Anti-FcγRIIB (CD32) Antibodies Differentially Modulate Murine FVIII-Specific Recall Response in vitro.

Vollack N, Friese J, Bergmann S, Cragg MS, Tiede A, Werwitzke S.

Scand J Immunol. 2017 Aug;86(2):91-99. doi: 10.1111/sji.12573.

10.

Frequency and epitope specificity of anti-factor VIII C1 domain antibodies in acquired and congenital hemophilia A.

Kahle J, Orlowski A, Stichel D, Healey JF, Parker ET, Jacquemin M, Krause M, Tiede A, Schwabe D, Lollar P, Königs C.

Blood. 2017 Aug 10;130(6):808-816. doi: 10.1182/blood-2016-11-751347. Epub 2017 May 15.

11.

CD32 inhibition and high dose of rhFVIII suppress murine FVIII-specific recall response by distinct mechanisms in vitro.

Vollack N, Friese J, Bergmann S, Tiede A, Werwitzke S.

Thromb Haemost. 2017 Aug 30;117(9):1679-1687. doi: 10.1160/TH17-03-0201. Epub 2017 May 11.

PMID:
28492697
12.

Acquired hemophilia A: Updated review of evidence and treatment guidance.

Kruse-Jarres R, Kempton CL, Baudo F, Collins PW, Knoebl P, Leissinger CA, Tiede A, Kessler CM.

Am J Hematol. 2017 Jul;92(7):695-705. doi: 10.1002/ajh.24777. Epub 2017 Jun 5. Review.

13.

PK-guided personalized prophylaxis with Nuwiq® (human-cl rhFVIII) in adults with severe haemophilia A.

Lissitchkov T, Rusen L, Georgiev P, Windyga J, Klamroth R, Gercheva L, Nemes L, Tiede A, Bichler J, Knaub S, Belyanskaya L, Walter O, Pasi KJ.

Haemophilia. 2017 Sep;23(5):697-704. doi: 10.1111/hae.13251. Epub 2017 Apr 27. Erratum in: Haemophilia. 2018 Jan;24(1):162.

PMID:
28452151
14.

Pharmacokinetics of a novel extended half-life glycoPEGylated factor IX, nonacog beta pegol (N9-GP) in previously treated patients with haemophilia B: results from two phase 3 clinical trials.

Tiede A, Abdul-Karim F, Carcao M, Persson P, Clausen WHO, Kearney S, Matsushita T, Negrier C, Oldenburg J, Santagostino E, Young G.

Haemophilia. 2017 Jul;23(4):547-555. doi: 10.1111/hae.13191. Epub 2017 Feb 24.

PMID:
28233381
15.

Thromboembolic Risks of Non-Factor Replacement Therapies in Hemophilia.

Tiede A.

Hamostaseologie. 2017;37(4):307-310. doi: 10.5482/20170004. Epub 2017 Dec 28. No abstract available.

PMID:
29582931
16.

Interim results from a large multinational extension trial (guardian(™) 2) using turoctocog alfa for prophylaxis and treatment of bleeding in patients with severe haemophilia A.

Lentz SR, Cerqueira M, Janic D, Kempton C, Matytsina I, Misgav M, Oldenburg J, Ozelo M, Recht M, Rosholm A, Savic A, Suzuki T, Tiede A, Santagostino E.

Haemophilia. 2016 Sep;22(5):e445-9. doi: 10.1111/hae.12990. Epub 2016 Jun 13. No abstract available.

PMID:
27291066
17.

Successful immune tolerance induction using turoctocog alfa in an adult haemophilia A patient.

Feistritzer C, Wildner SM, Würtinger P, Nachbaur D, Tiede A, Steurer M.

Blood Coagul Fibrinolysis. 2017 Mar;28(2):181-184. doi: 10.1097/MBC.0000000000000547.

PMID:
27152926
18.

Diagnostic and prognostic value of factor VIII binding antibodies in acquired hemophilia A: data from the GTH-AH 01/2010 study.

Werwitzke S, Geisen U, Nowak-Göttl U, Eichler H, Stephan B, Scholz U, Holstein K, Klamroth R, Knöbl P, Huth-Kühne A, Bomke B, Tiede A.

J Thromb Haemost. 2016 May;14(5):940-7. doi: 10.1111/jth.13304. Epub 2016 Apr 22.

19.

Diagnosis, prevention, and management of bleeding episodes in Philadelphia-negative myeloproliferative neoplasms: recommendations by the Hemostasis Working Party of the German Society of Hematology and Medical Oncology (DGHO) and the Society of Thrombosis and Hemostasis Research (GTH).

Appelmann I, Kreher S, Parmentier S, Wolf HH, Bisping G, Kirschner M, Bergmann F, Schilling K, Brümmendorf TH, Petrides PE, Tiede A, Matzdorff A, Griesshammer M, Riess H, Koschmieder S.

Ann Hematol. 2016 Apr;95(5):707-18. doi: 10.1007/s00277-016-2621-2. Epub 2016 Feb 26. Review.

PMID:
26916570
20.

Anti-factor VIII IgA as a potential marker of poor prognosis in acquired hemophilia A: results from the GTH-AH 01/2010 study.

Tiede A, Hofbauer CJ, Werwitzke S, Knöbl P, Gottstein S, Scharf RE, Heinz J, Groß J, Holstein K, Dobbelstein C, Scheiflinger F, Koch A, Reipert BM.

Blood. 2016 May 12;127(19):2289-97. doi: 10.1182/blood-2015-09-672774. Epub 2016 Feb 24.

Supplemental Content

Loading ...
Support Center